New hypertension drug shows promise in early safety trial
NCT ID NCT06905327
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called QCZ484 in 56 healthy volunteers and people with mild hypertension. The main goal was to check safety and how the body handles the drug. Participants received a single injection of either QCZ484 or a placebo, and researchers monitored for side effects and lab changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QCZ484
What this could lead to
If successful, this could lead to a new treatment option for mild hypertension.
What could go wrong
This is an early Phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Herston, Queensland, 4006, Australia
-
Novartis Investigative Site
Morayfield, Queensland, 4506, Australia
-
Novartis Investigative Site
Adelaide, 5000, Australia
-
Novartis Investigative Site
Auckland, 0622, New Zealand